1. Home
  2. EXEL
  3. EXEL News

Latest Exelixis Inc. (EXEL) News on May 10, 2025

Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
EXEL

Zacks

2 days ago

Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
EXEL

Business Wire

2 days ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

EXEL

Argus Research

3 days ago

EXEL: Lowering target price to $40.00

Exelixis, Inc. (EXEL): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy
EXEL

Insider Monkey

6 days ago

Exelixis, Inc. (EXEL): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy

Here's Why Exelixis (EXEL) is a Strong Momentum Stock
EXEL

Zacks

8 days ago

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
EXEL

Business Wire

10 days ago

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
EXEL

Zacks

11 days ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points
EXEL

Investor's Business Daily

14 days ago

MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points

Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
EXEL

Zacks

14 days ago

Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?

Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline
EXEL

Zacks

16 days ago

Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline

Here's Why Exelixis (EXEL) is a Strong Value Stock
EXEL

Zacks

16 days ago

Here's Why Exelixis (EXEL) is a Strong Value Stock

EXEL

Argus Research

17 days ago

EXEL: What does Argus have to say about EXEL?

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release
EXEL

Zacks

18 days ago

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

High Growth Tech Stocks To Watch In The US April 2025
EXEL

Simply Wall St.

22 days ago

High Growth Tech Stocks To Watch In The US April 2025

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
EXEL

Zacks

24 days ago

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

EXEL

Argus Research

24 days ago

EXEL: Raising target price to $40.00

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
EXEL

Zacks

a month ago

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
EXEL

Zacks

a month ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

EXEL

Argus Research

a month ago

EXEL: Lowering target price to $37.00

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
EXEL

Zacks

a month ago

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

The Smartest Biotech Stocks to Buy With $50
EXEL

Motley Fool

a month ago

The Smartest Biotech Stocks to Buy With $50

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More
EXEL

Zacks

a month ago

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?
EXEL

Insider Monkey

a month ago

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?

EXEL

Argus Research

a month ago

EXEL: Lowering target price to $40.00

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
EXEL

Zacks

a month ago

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi
EXEL

TipRanks

a month ago

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi

Exelixis to present positive preclinical data across pipeline portfolio at AACR
EXEL

TipRanks

a month ago

Exelixis to present positive preclinical data across pipeline portfolio at AACR

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?
EXEL

Zacks

a month ago

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET
EXEL

Simply Wall St.

a month ago

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET

EXEL

MT Newswires

a month ago

Exelixis Gets FDA Approval for Drug Treating Patients With Previously Treated Advanced Neuroendocrine Tumors

Here's Why Exelixis (EXEL) is a Strong Growth Stock
EXEL

Zacks

a month ago

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
EXEL

Business Wire

a month ago

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

EXEL

Argus Research

a month ago

EXEL: Raising target price to $41.00

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
EXEL

Business Wire

a month ago

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally
EXEL

Investor's Business Daily

2 months ago

Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally

Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?
EXEL

Zacks

2 months ago

Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
EXEL

Zacks

2 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Exelixis Growth Continues with Big Money Boosts
EXEL

FX Empire

2 months ago

Exelixis Growth Continues with Big Money Boosts

Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires
EXEL

Insider Monkey

2 months ago

Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires

Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?
EXEL

Zacks

2 months ago

Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?

EXEL

MT Newswires

2 months ago

RBC Raises Price Target on Exelixis to $40 From $38, Keeps Outperform Rating

EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
EXEL

Zacks

2 months ago

EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
EXEL

Zacks

2 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

EXEL

Argus Research

2 months ago

EXEL: Raising target price to $42.00

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
EXEL

Zacks

2 months ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Exploring 3 High Growth Tech Stocks In The US Market
EXEL

Simply Wall St.

2 months ago

Exploring 3 High Growth Tech Stocks In The US Market

Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now?
EXEL

Insider Monkey

2 months ago

Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now?

Exelixis focuses on future growth despite COSMIC-313 trial challenges
EXEL

Pharmaceutical Technology

2 months ago

Exelixis focuses on future growth despite COSMIC-313 trial challenges

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors
EXEL

Zacks

2 months ago

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

EXEL

Argus Research

2 months ago

EXEL: Raising target price to $40.00

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
EXEL

Business Wire

2 months ago

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

Analysts Give The Green Light To Two Stocks With Brighter Outlook Than Even Nvidia
EXEL

Investor's Business Daily

2 months ago

Analysts Give The Green Light To Two Stocks With Brighter Outlook Than Even Nvidia

EXEL or TECH: Which Is the Better Value Stock Right Now?
EXEL

Zacks

3 months ago

EXEL or TECH: Which Is the Better Value Stock Right Now?

EXEL

MT Newswires

3 months ago

Wells Fargo Downgrades Exelixis to Equalweight From Overweight, Price Target is $36

Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks
EXEL

Insider Monkey

3 months ago

Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks

Why Exelixis Stock Trounced the Market on Thursday
EXEL

Motley Fool

3 months ago

Why Exelixis Stock Trounced the Market on Thursday

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
EXEL

Benzinga

3 months ago

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point
EXEL

Simply Wall St.

3 months ago

Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point

EXEL

MT Newswires

3 months ago

Exelixis Board Authorizes Additional Share Buyback Program of Up To $500 Million; Shares Advance After Hours

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
EXEL

Business Wire

3 months ago

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
EXEL

Zacks

3 months ago

Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
EXEL

Zacks

3 months ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

EXEL

MT Newswires

3 months ago

Exelixis Insider Sold Shares Worth $1,541,343, According to a Recent SEC Filing

EXEL

Argus Research

3 months ago

EXEL: Raising target price to $37.00

Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?
EXEL

Zacks

3 months ago

Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?

International Markets and Exelixis (EXEL): A Deep Dive for Investors
EXEL

Zacks

3 months ago

International Markets and Exelixis (EXEL): A Deep Dive for Investors

Five-year results see Exelixis’ RCC therapy extending overall survival
EXEL

Clinical Trials Arena

3 months ago

Five-year results see Exelixis’ RCC therapy extending overall survival

Exelixis Full Year 2024 Earnings: EPS Beats Expectations
EXEL

Simply Wall St.

3 months ago

Exelixis Full Year 2024 Earnings: EPS Beats Expectations

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
EXEL

Business Wire

3 months ago

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
EXEL

Zacks

3 months ago

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
EXEL

Business Wire

3 months ago

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
EXEL

Zacks

3 months ago

EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus

Exelixis Inc (EXEL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
EXEL

GuruFocus.com

3 months ago

Exelixis Inc (EXEL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Exelixis (EXEL) Q4 2024 Earnings Call Transcript
EXEL

Motley Fool

3 months ago

Exelixis (EXEL) Q4 2024 Earnings Call Transcript

Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
EXEL

Zacks

3 months ago

Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates
EXEL

Zacks

3 months ago

Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates

EXEL

MT Newswires

3 months ago

Exelixis' Q4 Non-GAAP Earnings, Revenue Rise

EXEL

Associated Press Finance

3 months ago

Exelixis: Q4 Earnings Snapshot

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
EXEL

Business Wire

3 months ago

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

2 Stocks to Buy With Less Than $40
EXEL

Motley Fool

3 months ago

2 Stocks to Buy With Less Than $40

The 10 best stocks of the last decade
EXEL

Quartz

3 months ago

The 10 best stocks of the last decade

Zacks.com featured highlights include Pilgrim's Pride, Exelixis, Synchrony and United Airlines
EXEL

Zacks

3 months ago

Zacks.com featured highlights include Pilgrim's Pride, Exelixis, Synchrony and United Airlines

EXEL or TECH: Which Is the Better Value Stock Right Now?
EXEL

Zacks

3 months ago

EXEL or TECH: Which Is the Better Value Stock Right Now?

Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
EXEL

Zacks

3 months ago

Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics
EXEL

Zacks

3 months ago

Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics

EXEL

Argus Research

3 months ago

EXEL: What does Argus have to say about EXEL?

Exploring High Growth Tech Stocks in February 2025
EXEL

Simply Wall St.

3 months ago

Exploring High Growth Tech Stocks in February 2025

Here's Why Exelixis (EXEL) is a Strong Value Stock
EXEL

Zacks

3 months ago

Here's Why Exelixis (EXEL) is a Strong Value Stock

Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?
EXEL

Zacks

3 months ago

Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?

EXEL

Argus Research

3 months ago

EXEL: Rating increased to a BUY

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
EXEL

Business Wire

3 months ago

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
EXEL

Zacks

3 months ago

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform
EXEL

Zacks

3 months ago

Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform

EXEL

MT Newswires

3 months ago

Truist Lifts Price Target on Exelixis to $43 From $42, Keeps Buy Rating

EXEL

MT Newswires

3 months ago

Morgan Stanley Upgrades Exelixis to Overweight From Equalweight, Raises Price Target to $40 From $30

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025
EXEL

Business Wire

3 months ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025

EXEL

MT Newswires

4 months ago

Exelixis Reports Results on Drug Study to Treat Advanced Gastrointestinal Neuroendocrine Tumors

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
EXEL

Business Wire

4 months ago

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33?
EXEL

GuruFocus.com

4 months ago

Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33?

Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns
EXEL

GuruFocus.com

4 months ago

Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns

Share on Social Networks: